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OBJECTIVES The purpose of this study was to determine whether atorvastatin, a 3-hydroxy-3-
methylglutaryl (HMG)-co-enzyme A (CoA) reductase inhibitor, limits myocardial necrosis
when administered as an adjunct to reperfusion.
BACKGROUND Statins inhibit HMG-CoA reductase to reduce the synthesis of cholesterol. However, it is
proposed that statins have cardiovascular effects beyond their ability to lower cholesterol,
possibly via recruitment of phosphatidyl inositol 3-kinase (PI3K) and the serine/threonine
kinase, Akt. This signaling pathway has recently been linked to growth factor–mediated
reperfusion salvage.
METHODS Isolated perfused mouse hearts were subjected to 35 min of global ischemia and reperfused for
30 min in the presence of incremental concentrations of atorvastatin. Infarct size was
determined by triphenyltetrazolium chloride staining, and the activity of the PI3K signaling
cascade was determined by Western blot analysis.
RESULTS We found that there was a profound dose-dependent reduction of infarct size with
atorvastatin in the range of 25 to 100 mol/l (optimal protection was seen at 50 mol/l with
infarct size of 16  2% vs. control, 33  2%, p  0.01). Moreover, this protection was
sensitive to inhibition with the PI3 kinase inhibitor, wortmannin, and was absent in
endothelial nitric oxide synthase (eNOS) knockout mice. Western blot analysis revealed that
atorvastatin resulted in rapid activation of the PI3K/Akt signaling cascade (within 5 min) and
that both Akt and eNOS phosphorylation were significantly increased by 4.1-fold and
2.9-fold, respectively (p  0.01). Moreover, phosphorylation of the PI3K substrates was
abrogated by the administration of wortmannin.
CONCLUSIONS Atorvastatin attenuates lethal reperfusion-induced injury in a manner that is reliant on PI3K
and Akt activity and the presence and activity of eNOS. (J Am Coll Cardiol 2003;41:
508–15) © 2003 by the American College of Cardiology Foundation
Reperfusion is a prerequisite to myocardial salvage after
coronary occlusion. Although reperfusion is undeniably
beneficial, it is perhaps not without risk. While there is
some controversy regarding reperfusion injury as an event
independent of the antecedent ischemia (1,2), we and others
propose that this form of injury may be amenable to
pharmacologic manipulation (3,4). Recently, we have iden-
tified a potential role for the phosphatidyl inositol 3-kinase
(PI3K) and the downstream target, the serine/threonine
kinase, Akt pathway in ameliorating reperfusion injury
(5,6). Indeed, using the growth factors, insulin and insulin-
like growth factor-1, it has been shown that recruitment of
the PI3K/Akt signaling cascade upon reperfusion may be
beneficial in limiting myocardial/myocyte cell death (5–8).
Moreover, over-expression of Akt in rats attenuates cell
death and myocardial dysfunction after injurious ischemia
(9).
3-Hydroxy-3-methylglutaryl (HMG)-co-enzyme A
(CoA) reductase inhibitors have been increasingly pre-
scribed for patients with cardiovascular disease after robust
outcome results from both primary (10) and secondary
prevention studies (11). It is, however, becoming clear that
statins appear to have pleiotropic effects beyond their ability
to lower cholesterol (12). Indeed, statins have been shown
to be beneficial in such diverse conditions as Alzheimer’s
disease (13) and osteoporosis (14).
The signaling sequelae of HMG-CoA reductase remain
unclear. In attenuating HMG-CoA reductase activity,
statins reduce cellular content of the products of the
mevalonate metabolic pathway that leads to the synthesis of
cholesterol. Many of these products, the isoprenoids, are
thought to be essential for the growth and proliferation of
eukaryotic cells. One important isoprenoid is farnesiol,
which is capable of binding covalently to a number of
guanosine triphosphate–binding proteins such as p21ras; a
potentially important component of growth factor–
stimulated signaling (15). Another is geranylgeranyl pyro-
phosphate, which through geranylgeranylation of the
guanosine triphosphatase Rho appears to down-regulate
endothelial nitric oxide synthase (eNOS) messenger ribo-
nucleic acid (mRNA) (16). This effect may help to explain,
in part, why statins lead to increased eNOS mRNA in
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thrombocytes (17) and are able to reverse the down-
regulation of eNOS by low-density lipoprotein cholesterol
(18). Up-regulation of eNOS activity is of potential interest
in reperfusion injury; recent work with nitric oxide (NO)
donors suggests that NO attenuates myocardial dysfunction
after an injurious ischemia/reperfusion insult (19,20).
Recently, HMG-CoA reductase inhibitors have been
shown to recruit the PI3K and Akt signaling cascade in
endothelial cell lines, although not in neonatal rat cardiac
myocytes (21). However, simvastatin has been shown to
possess infarct sparing properties and is capable of attenu-
ating reperfusion myocardial dysfunction in adult rats
(22,23). Evidence to support a potential role of statins in
recruiting the cell-survival PI3K/Akt pathway in the car-
diovascular system is twofold. First, atorvastatin adminis-
tration to aortic endothelium results in a decrease in
caveolin abundance and, thus, reduced inhibitory binding of
eNOS. This is correlated with recruitment of eNOS into an
eNOS/heat stress protein 90/Akt complex, leading to the
phosphorylation of eNOS at serine 1177 (24). Second,
statins have been shown to have both a proliferative and
anti-proliferative effect on the vasculature. At low concen-
trations, statins have angiogenic properties, whereas at
higher concentrations they are anti-proliferative (25); the
angiogenic process has been linked to the recruitment of the
PI3K/Akt pathway and phosphorylation of eNOS (21).
Thus, we hypothesized that exposure of the normo-
cholesterolemic adult heart to the HMG-CoA reductase
inhibitor, atorvastatin, after a period of injurious ischemia,
would recruit the PI3K pathway and lead to cardioprotec-
tion. Because the optimal concentration of atorvastatin that
would prove to be protective was unknown, the initial aim
was to construct a dose–response curve using concentrations
of atorvastatin that are clinically representative of those used
to reduce cholesterol in hypercholesterolemic patients. Sec-
ondary aims were to determine whether there was a role for
the PI3K/Akt signaling cascade, whether recruitment of
eNOS occurs, and whether the activity of this pathway is
essential to HMG-CoA reductase inhibitor–induced pro-
tection.
METHODS
All work was conducted in accordance with the Guidelines
on the Operation of the Animals (Scientific Procedures) Act
1986, published by The Stationery Office (London, UK).
Wortmannin was purchased from Sigma (Poole, UK).
Dimethyl sulfoxide (DMSO; BDH Laboratory Supplies,
Poole, UK) was used as the solvent for wortmannin and
used at a final concentration in the perfusion buffer of
0.001%. Atorvastatin was kindly supplied by Pfizer and was
dissolved in methanol (BDH Laboratory Supplies, Poole,
UK) at 5 mg/100 l. Final concentration of methanol in the
perfusion buffer did not exceed 0.001%.
Mice were obtained from the breeding colony kept at
University College, London, bred under license from Jack-
son Laboratories. Both eNOS wild-type (parental wild-
type, based on C57BL/6J background) and eNOS knockout
(KO) mice were used in the present study; a total of 75 mice
were used. Three mice were excluded before starting the
experimental protocol. No hearts were excluded after the
onset of the ischemia/reperfusion protocol.
Langendorff perfusion. Male and female eNOS KO mice
(3 to 4 months of age, 20 to 30 g weight) were randomly
attributed to either control or treatment groups. Heart
isolation and Langendorff perfusion (with modified Krebs-
Henseleit buffer consisting of NaCl 118 mmol/l, NaCO3
24 mmol/l, glucose 10 mmol/l, KCl 4 mmol/l, NaH2PO4
1.0 mmol/l, Na2 ethylenediaminetetraacetic acid 0.5 mmol/l,
MgCl2 1.2 mmol/l, CaCl2 2.5 mmol/l) were performed as
previously described (26). In brief, mice were anesthetized
with an intra-peritoneal injection of 60 mg/kg pentobarbi-
tone. Hearts were then harvested via a para-medial thora-
cotomy and rapidly transferred to a dissection dish filled
with ice cold Krebs-Henseleit buffer. The aorta was cannu-
lated with a 21-gauge murine cannula and transferred to the
Langendorff rig. Hearts were paced throughout the stabili-
zation period and during the final 20 min of reperfusion
(600 beats/min).
Western blotting. Western blot analysis was performed as
previously described (26). Lanes were loaded at 60 g/lane.
Loading was confirmed both by Ponceau staining of the
membranes after transfer from the polyacrylamide gel and
by quantification of the relevant non-phosphorylated pro-
tein (Akt or eNOS) by Western blot analysis. The mem-
branes were probed with rabbit polyclonal antibodies for
Akt, phospho- (serine 473) Akt, eNOS, and phospho-
(serine 1177) eNOS antibodies purchased from Cell Sig-
nalling (Hitchin, UK) and used in accordance with the
manufacturer’s instructions. Quantification was achieved
using the enhanced chemiluminescence technique, with
exposure to photographic film. The developed films were
scanned using a flatbed document scanner, and the relative
densitometry was assessed using the National Institutes of
Health (NIH) Shareware program, NIH Image 1.62.
Experimental protocols. Langendorff perfusions were split
into two phases: phase A for infarct size analysis and phase
B for Western blot analysis. All hearts were subjected to
35 min of global, normothermic ischemia. Hearts were then
either reperfused for 30 min and stained with triphenyl
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509JACC Vol. 41, No. 3, 2003 Bell and Yellon
February 5, 2003:508–15 Atorvastatin Attenuates Reperfusion Injury via PI3K
tetrazolium before planimetry in phase A, or they were
reperfused for 5, 10, or 15 min and snap-frozen in phase B.
PHASE A. The eNOS wild-type and eNOS KO hearts
were randomized to receive one of the following treatments
from the onset of reperfusion: 1) vehicle (n  6 each for
Krebs-Henseleit buffer, 0.001% methanol, or 0.001%
DMSO); 2) atorvastatin (n  6 each for 5, 25, 50, and
100 mol/l); and 3) wortmannin 100 nmol/l in the presence
or absence of 25 mol/l atorvastatin.
PHASE B. These experiments were divided into two groups
as follows: 1) The eNOS wild-type hearts were randomized
into 5-, 10-, or 15-min reperfusion groups in the presence
or absence of 25 mol/l atorvastatin; 2) The eNOS wild-
type hearts were randomized to receive either vehicle or
25 mol/l atorvastatin in the presence or absence of
wortmannin, 100 nmol/l, whereas eNOS KO hearts were
randomized to receive either vehicle or 25 mol/l atorva-
statin.
Infarct size analysis. Infarct size was determined by the
triphenyl tetrazolium chloride (TTC) staining technique as
previously described (26). In brief, the hearts at the end of
the experimental protocol were infused with TTC in
phosphate-buffered solution (pH 7.4). This turns viable
tissue a dark red color, whereas non-viable, necrotic myo-
cardium appears pale. The hearts were incubated for 10 min
in TTC before destaining in 10% formaldehyde solution to
increase contrast between necrotic and viable myocardium.
Infarct size is expressed as an infarct-to-risk-zone ratio
(when the risk zone in the global ischemic heart is the whole
ventricular volume). Data are presented as a percentage 
SEM.
Statistical analysis. All values are expressed as mean 
SEM. Differences in continuously distributed variables be-
tween predetermined experimental groups were analyzed
using one-way analysis of variance followed by Fisher’s
protected test of least significant difference. A p value of
0.05 was considered to be at the limit of statistical signifi-
cance.
RESULTS
Does atorvastatin limit infarct size when administered as
an adjunct to reperfusion? To determine whether atorva-
statin is capable of attenuating myocardial infarction (MI)
in this isolated mouse model of ischemia and reperfusion,
we compared wild-type hearts, in the presence or absence of
the solute vehicle, methanol (0.001%) added at reperfusion,
with incremental concentrations of atorvastatin adminis-
tered upon reperfusion. Over a concentration range of 25 to
100 mol/l, atorvastatin significantly attenuated infarction
(p  0.01), with maximal protection observed with the
50 mol/l dose. Infarct-to-risk-zone ratios were 26  3%,
19  2%, 16  2%, and 21  3% for 5, 25, 50, and
100 mol/l, versus Krebs-Henseleit and methanol vehicle
control 32  2% and 33  2%, respectively (Fig. 1).
Does atorvastatin administration at reperfusion result in
increased activity of PI3K and Akt? To determine
whether atorvastatin-mediated reperfusion salvage is medi-
ated by the recruitment of the PI3K/Akt signaling cascade,
we measured the phosphorylation of the substrates of each
of these protein kinases, Akt and eNOS, respectively. In
control hearts, modest phosphorylation of Akt and eNOS
was observed 10 min after the onset of reperfusion (Figs. 2
and 3), although over the time period examined (15 min of
reperfusion ) there was no statistically significant increase in
the activity of either PI3K or Akt. In contrast, treatment of
the hearts at reperfusion with 25 mol/l atorvastatin re-
sulted in a significant increase of phosphorylation at all time
points measured, suggesting that atorvastatin results in a
rapid and more robust activation of the PI3K signaling
cascade. Densitometry data indicate that the total Akt and
eNOS phosphorylation after reperfusion in the atorvastatin
group were 4.1-fold and 2.9-fold greater, respectively (p 
0.001), than over the same 15-min period in control hearts.
Performing a simple regression plot between the quantifi-
cation of phospho-Akt and phospho-eNOS resulted in a
robust correlation (r2 0.7, p  0.001 with a gradient of
0.8) indicating a direct relationship between the phosphor-
ylation of Akt and the phosphorylation of eNOS.
Is increased PI3K activity essential for reperfusion sal-
vage, or an epiphenomenon? To determine whether the
increase in PI3K activity is functionally related to atorva-
statin reperfusion salvage or merely an epiphenomenon, we
used the PI3K inhibitor, wortmannin (100 nmol/l) upon
reperfusion in the presence or absence of atorvastatin
(25 mol/l). Wortmannin alone had no impact on infarct
Figure 1. Atorvastatin dose–response curve. Incremental concentrations of
atorvastatin resulted in a dose-dependent reduction of infarct size, peaking
with 50 mol/l (**p  0.001 vs. control). Protection with 100 mol/l was,
however, less than that seen at 50 mol/l (*p  0.05 vs. control).
510 Bell and Yellon JACC Vol. 41, No. 3, 2003
Atorvastatin Attenuates Reperfusion Injury via PI3K February 5, 2003:508–15
size (32 2% vs. control, 34 2%). However, wortmannin
completely abrogated the protection observed with atorva-
statin (33  2% vs. atorvastatin alone, 19  2% and control
34  2%, p  0.05, Fig. 4).
Is eNOS required for atorvastatin-mediated protec-
tion? To determine whether eNOS is essential in the
mediation of atorvastatin reperfusion salvage, we adminis-
tered the cardioprotective dose of atorvastatin (25 mol/l)
to eNOS KO hearts. In contrast to the eNOS wild-type
hearts previously studied, we found no protection (32  1%
vs. control, 31  1%, Fig. 5).
Is PI3K activity modified in eNOS KO hearts and
inhibited by wortmannin? To determine whether the loss
of atorvastatin-mediated protection that was observed in
eNOS KO hearts and eNOS wild-type hearts treated with
wortmannin was meditated by inhibition of PI3K activity,
we assayed Akt phosphorylation in KO and wortmannin-
treated hearts. Wortmannin administration significantly
attenuated atorvastatin-triggered Akt phosphorylation to
below the level seen in control hearts (143  6 AU vs.
atorvastatin alone, 772 31 AU and control, 422 52 AU,
p  0.001 and p  0.01, respectively, Fig. 6).
Although no protection was observed as a result of
atorvastatin administration in eNOS KO hearts, a similar
level of Akt phosphorylation was nonetheless observed in
KO hearts as it was in wild-type hearts (866  32 AU vs.
wild-type atorvastatin-treated hearts, 772  31 AU, p 
0.05). Thus PI3K activity is indeed increased by
atorvastatin-treated hearts despite the absence of cardiopro-
tection.
DISCUSSION
This study identifies the HMG-CoA reductase inhibitor,
atorvastatin, as a drug capable of attenuating MI when
administered as an adjunct to reperfusion, in a setting that
is independent of cholesterol lowering. The data demon-
strate, for the first time, that atorvastatin administered as an
adjunct to reperfusion results in significant, dose-dependent
cardioprotection, with an optimal concentration range be-
tween 25 and 100 mol/l and maximal protection at
50 mol/l. This study also identifies a key signaling pathway
by which this protection at reperfusion is wrought: the PI3K
signaling cascade—the first time that statins have been
shown to regulate this kinase pathway in myocardium.
Previous work has shown that statins may have quite
opposing effects on tissue Akt activation and cellular sur-
vival, with up-regulation demonstrated in endothelial cells
(21), no effect on neonatal myocytes (21), and a down-
regulation in smooth muscle cells (27,28). Interestingly, our
preliminary data in unstressed, Langendorff perfused, adult
mouse myocardium indicated that brief (10-min) adminis-
tration of 25 mol/l atorvastatin did not enhance PI3K
activity, as determined by the quantification of Akt phos-
phorylation by Western blotting (data not shown). How-
ever, we show here that 25 mol/l atorvastatin does signif-
Figure 2. The Akt phosphorylation time-course. Administration of 25 mol/l atorvastatin to wild-type hearts at the start of reperfusion after a period of
ischemia resulted in a robust and rapid increase in Akt phosphorylation (4.1-fold greater than that seen in control hearts, p  0.001).
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icantly increase phosphorylation of both Akt and eNOS in
the post-ischemic myocardium (although the specific cell
types have not been delineated). These data provide evi-
dence that the PI3K may be playing an important role
during the early reperfusion period, as has been suggested by
recent work by ourselves and others with insulin both in
Figure 3. The eNOS phosphorylation time-course. Administration of 25 mol/l atorvastatin at the start of reperfusion after a period of ischemia resulted
in a similar pattern of phosphorylation of eNOS to that seen with Akt, with a significant 2.8-fold increase over control (p  0.001).
Figure 4. The PI3K inhibitor, wortmannin, inhibits the reperfusion salvage seen with 25 mol/l atorvastatin. Wortmannin administered alone had no
impact on infarction (*p  0.05, atorvastatin group vs. control and wortmannin plus atorvastatin).
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vitro and in vivo (6,29). The PI3K hypothesis of reperfusion
salvage is further supported by the data obtained after the
administration of the PI3K inhibitor wortmannin. Not only
does wortmannin lead to a significant attenuation of Akt
phosphorylation associated with atorvastatin administra-
tion, wortmannin also abrogates atorvastatin-mediated pro-
tection. Thus, it appears that PI3K activity is essential in
attenuating reperfusion injury.
A significant number of downstream targets for the PI3K
signaling cascade have been identified (30), although those
that are essential for early reperfusion salvage are not clear.
One candidate that we have recently identified is the
ribosomal p70S6 kinase (6). In this study, using insulin to
trigger reperfusion salvage via insulin tyrosine kinase linked
receptor, we were able to maintain the pro-apoptotic Bcl-2
family member, Bad, in a phosphorylated and, therefore,
inactivated state (6,31). In the present study, we have
investigated the role of an alternative target of Akt, namely
eNOS (32). Concurrent with the rapid increase in Akt
phosphorylation observed in hearts treated with atorvastatin
administered at reperfusion, we see a significant and parallel
increase of the phosphorylation of eNOS. Comparing the
phosphorylation densitometry of both Akt and eNOS
blotted from the same membrane, we find a significant and
high correlation between the two events, implying that
phosphorylation of eNOS is closely related to phosphory-
lation and activity of Akt. Significantly, the protection
wrought by the administration of atorvastatin is completely
absent in the eNOS KO heart. This suggests that eNOS is
pivotal to the PI3K signaling cascade; Western blot analysis
demonstrates that eNOS KO hearts are not deficient in the
activity of PI3K, as measured by Akt phosphorylation.
Therefore, it would seem that in this model of ischemia and
reperfusion, PI3K activation alone is not sufficient to pro-
vide protection against infarction in the reperfused heart.
The concentrations of atorvastatin used in the present
investigation are representative of top-end oral administra-
tion of the drug used in the management of hypercholes-
terolemic patients. Lower concentrations of atorvastatin
have been found to be beneficial in promoting angiogenesis;
it is interesting to note, however, that the concentrations
used in the present study are anti-angiogenic according to
recent work by Weis et al. (25). The duration of adminis-
tration is the determining factor in producing this effect; in
the present model we are investigating the immediate direct
myocardial protective properties of statins, whereas the
angiogenic effects are found with long-term administration,
suggesting a dichotomy of beneficial concentration depend-
ing on the period of the treatment regime. That a “high
dose” of statin is appropriate in the short-term setting of
reperfusion injury management is supported by the recent
work of Di Napoli et al. (22) with 25 mol/l simvastatin in
a working heart model of ischemia/reperfusion. In that
study, simvastatin was administered with the onset of
15 min of global ischemia and at 180 min of reperfusion;
high-dose simvastatin was found to be cardioprotective and,
moreover, dependent on NO synthase activity.
Isolated, crystalloid perfused hearts were used in the
present study to remove the potentially confounding effects
of serum cholesterol, of actions on thrombocytes, and of the
neutrophil/endothelial interaction previously hypothesized
to be the mechanism of statin-mediated protection (17,33).
In this study, we demonstrate that atorvastatin is capable of
conferring protection on the reperfused myocardium inde-
pendently of these factors, suggesting a direct effect on the
myocardium of increasing the resistance to ischemia/
Figure 5. Reperfusion salvage seen with 25 mol/l atorvastatin is absent in eNOS KO mice. Although atorvastatin results in significant protection in the
wild-type hearts (WT), this protection was completely absent in the eNOS KO hearts (*p  0.001 atorvastatin vs. WT control).
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reperfusion injury, mediated by PI3K, Akt, and eNOS.
However, the isolated perfused model of ischemia and
reperfusion has limitations specifically related to the limited
time during which an isolated heart may be reperfused.
Although this limitation should be recognized in the con-
text of evolving MI and remodeling, we believe that the data
presented here provide an insight into the mechanisms by
which statins appear to confer additional protection on the
ischemic heart beyond the drugs’ ability to reduce serum
cholesterol (34,35).
In summary, we present evidence that the HMG-CoA
reductase inhibitor, atorvastatin, is capable of attenuating
ischemia/reperfusion injury when administered at the onset
of reperfusion. Moreover, we show that the mechanism of
action by which this protection is achieved is dependent on
the recruitment and activation of a signaling cascade involv-
ing PI3K, Akt, and eNOS. Moreover, this protection
appears to be mediated directly via the myocardium, inde-
pendently of circulating thrombocytes, neutrophils, and
other inflammatory moieties, and independently of a
cholesterol-lowering effect.
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